• Explore /
  • Poster
  • / Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress.

Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress.

Abstract Poster

Authors

null

Do-Youn Oh

Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea

Do-Youn Oh , Jin Won Kim , Hongjae Chon , Choong-kun Lee , Ji-Won Kim , Beodeul Kang , Hye Jin Choi , Se Jun Park , Jeesun Yoon , Myung Ah Lee

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04727996

DOI

10.1200/JCO.2022.40.4_suppl.TPS490

Abstract #

TPS490

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Jee Sun Yoon

First Author: Jia Fan

First Author: Zhen-gang Yuan

First Author: Do-Youn Oh